Published in Vaccine Weekly, September 28th, 2005
Study 1: Scientists review new recombinant serotypes of AAV (adeno-associated virus) vectors in a recent issue of Current Gene Therapy.
"AAV based vectors can achieve stable gene transfer with minimal vector related toxicities. AAV serotype 2 (AAV2) is the first AAV that was vectored for gene transfer applications. However, the restricted tissue tropism of AAV and its low transduction efficiency have limited its further development as vector," researchers in the United States report.
"Recent studies using vectors derived...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly